drugset / Trial / NCT03187496

Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers.

NCT03187496 ↗

Phase 1 Completed 24 enrolled Enanta Pharmaceuticals, Inc
NaSingle-groupOpen-labelBasic science

Summary

A non-randomized, multiple-dose, open-label, single sequence study to evaluate effect of concomitant administration of EDP-305 on the pharmacokinetics and safety of midazolam, caffeine, and rosuvastatin in healthy human volunteers.

Timeline

Start
2017-05-11
Primary completion
2017-06-01
Completion
2017-06-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Caffeine Small molecule — —
Subject EDP-305 Unknown — —
Subject Midazolam Small molecule — —
Subject Rosuvastatin Small molecule — —